Cyllene Therapeutics raised €33 million to test its approach in the HSV-based gene therapy space, taking aim at a different therapeutic area as it seeks to replicate the “Krystal Biotech blueprint.” The funding is positioned to extend the company’s platform and development path in a field where delivery and durability remain central constraints. The financing underscores continued investor appetite for targeted gene delivery, particularly when platform validation can be mapped to existing clinical proof points in similar viral vector mechanisms. For operators and partners, the key near-term question is how Cyllene’s therapeutic targeting and delivery performance translate from early studies into a clear clinical development plan that supports eventual regulatory filing timelines.